Abstract
There is increasing interest in the implementation of programmes to control nematodiases by chemotherapy, but no consensus on whether diagnostic screening before treatment is an essential component of such programmes. It is estimated that a screening component increases costs by a factor of 2–6 and may be beyond the economic and skill resources of endemic areas, but accords with accepted medical practice since only infected individuals are treated. In an attempt to examine this issue quantitatively, the relative risks of mass treatment and morbidity due to helminthiasis are compared. Age-and locality-targeting of mass treatment at populations at high risk of morbidity are proposed as procedures for further enhancing this risk differential. It is suggested that resolving the question of screening versus mass treatment requires more quantitative information than is currently available on the risk of side effects with treatment and the risk of morbidity with variable intensities of infection.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Transactions of the Royal Society of Tropical Medicine and Hygiene
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
